Our bodies are amazingly complex systems. Some estimates say there are more than 37 trillion cells in our bodies. That’s trillion with a “t”. Each of those cells communicates and signals with other cells, which makes our bodies one heck of a busy place to be.
Yet all this activity may owe much of its splendor and complexity to a relatively small number of starting materials. One key player may be a protein that acts like a “master switch,” determining whether a cell changes and multiplies or stays the same.
Starting out
But let’s begin at the beginning. We all start as a single fertilized egg that develops into embryonic stem cells, which in turn become adult stem cells, which then give rise to all the different cells, tissues, and structures in our body, such as our bones, brains, and blood.
But how do those cells know when to change, what to change into, and when to stop? Change too little and something is undeveloped. Change too much, and you risk the kind of explosive, uncontrolled multiplication of cells that you see in cancer.
So, clearly, understanding what controls those changes in stem cells, and how to use that knowledge, could have an enormous impact on our ability to use stem cells to treat a wide range of diseases.
What’s in a name, or a number
Now researchers at Mount Sinai have identified a single protein that appears to play a major role in this control process. The protein is called zinc finger protein 217 (ZFP217), and it controls genes that, in turn, control whether a cell changes into another kind of cell and how often it keeps dividing and multiplying.
The study is published in Cell Stem Cell, and there is some pretty complex science involved, but ultimately what it boils down to is that ZFP217 has an impact on m6A (scientists really need to start coming up with more imaginative names), which is a protein that helps determine if a gene is turned on or off. If turned on, the gene performs one function. If turned off, it doesn’t.
By blocking the action of m6A, ZFP217 can stop the process that allows stem cells to differentiate, or change, into other cells and also end their ability to keep renewing themselves.
But wait, there’s more!
Another important role ZFP217 plays is helping spur the growth of cancerous tumors. Too much of the protein lets these cells multiply in an unlimited, uncontrolled way, typical of the growth we see in tumors.
The study was done in mice, but in a news release, the lead study author, Martin Walsh, PhD, talked about the possible significance of the findings for people:
“The hope is that ZFP217 could be used to maintain supplies of therapeutic stem cells. At the same time, as the human ZPF217 is associated with poor survival in a variety of cancers, understanding how this protein operates in physiological conditions may help to predict cancer risk, achieve earlier diagnosis and provide novel therapeutic approaches.”
A deeper understanding of what makes some stem cells multiply and change into other cells could let researchers better use stem cells to develop new approaches to treating some of the most intractable diseases of our time.
If that happens, then ZFP217 might be a name to remember after all.
